Zeiss Pharma Profile
Key Indicators
- Authorised Capital ₹ 15.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 14.05 Cr
as on 24-10-2024
- Company Age 10 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 190.23 Cr
as on 24-10-2024
- Revenue -8.92%
(FY 2023)
- Profit -55.80%
(FY 2023)
- Ebitda -149.63%
(FY 2023)
- Net Worth 89.53%
(FY 2023)
- Total Assets -11.67%
(FY 2023)
About Zeiss Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 15.00 Cr and a paid-up capital of Rs 14.05 Cr.
The company currently has active open charges totaling ₹190.23 Cr.
The Key Managerial Personnel (KMP) at Zeiss Pharma Limited India are Vinij Gupta as CFO and Rupam as Company Secretary. Sat Pal, Vikas Gupta, Vinij Gupta, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24233HR2014PLC052139
- Company No.
052139
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
13 Mar 2014
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Zeiss Pharma?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinij Gupta  | CFO | 24-Apr-2016 | Current |
| Rupam | Company Secretary | 23-Jan-2024 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vikas Gupta | Whole-Time Director | 13-Mar-2014 | Current |
| Sat Pal | Director | 13-Mar-2014 | Current |
| Vinij Gupta | Director and Cfo | 13-Mar-2014 | Current |
| Neeraj Bansal | Director | 25-Apr-2016 | Current |
| Satyapal Bansal | Director | 25-Apr-2016 | Current |
Financial Performance of Zeiss Pharma.
Zeiss Pharma Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.92% decrease. The company also saw a substantial fall in profitability, with a 55.8% decrease in profit. The company's net worth Soared by an impressive increase of 89.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zeiss Pharma?
In 2023, Zeiss Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bansal Finefoods Private LimitedActive 12 years 4 monthsNeeraj Bansal and Satyapal Bansal are mutual person
Zeiss Pharmaceuticals Private LimitedActive 20 years 10 monthsSat Pal, Vikas Gupta and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 21 Aug 2017 | ₹10.00 Cr | Open |
Hdfc Bank Limited Creation Date: 30 Nov 2015 | ₹180.23 Cr | Open |
How Many Employees Work at Zeiss Pharma?
Zeiss Pharma has a workforce of 155 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zeiss Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zeiss Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
